 | • レポートコード：QY2207C3465 • 出版社/出版日：QYResearch / 2022年7月11日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Multi User | ￥1,087,800 (USD7,350) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症のパンデミックにより、世界の移植片対宿主病治療の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に移植片対宿主病治療の世界市場のxxx％を占める「エタネルセプト」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「急性GVHD」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の移植片対宿主病治療の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの移植片対宿主病治療市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの移植片対宿主病治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 移植片対宿主病治療のグローバル主要メーカーには、AbbVie Inc.、Acrofan、Astellas Pharma Inc.、Bristol-Myers Squibb Company、ElsaLys Biotech SA、F. Hoffmann-La Roche AG、Johnson & Johnson、Mallinckrodft PLC、Merck & Co., Inc.、Mesoblast Limited、Neovii Biotech GmbH、Novartis AG、Ocugen, Inc.、Pfizer Inc、Pluristem Therapeutics Inc.、Samedan Ltd、Sanofi SA、Soligenix, Inc.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 移植片対宿主病治療市場は、種類と用途によって区分されます。世界の移植片対宿主病治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 エタネルセプト、モノクローナル抗体、サリドマイド、チロシンキナーゼ阻害剤、mTOR阻害剤 【用途別セグメント】 急性GVHD、慢性GVHD、予防GVHD 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 移植片対宿主病治療製品概要 - 種類別市場（エタネルセプト、モノクローナル抗体、サリドマイド、チロシンキナーゼ阻害剤、mTOR阻害剤） - 用途別市場（急性GVHD、慢性GVHD、予防GVHD） - 調査の目的 ・エグゼクティブサマリー - 世界の移植片対宿主病治療販売量予測2017-2028 - 世界の移植片対宿主病治療売上予測2017-2028 - 移植片対宿主病治療の地域別販売量 - 移植片対宿主病治療の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別移植片対宿主病治療販売量 - 主要メーカー別移植片対宿主病治療売上 - 主要メーカー別移植片対宿主病治療価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（エタネルセプト、モノクローナル抗体、サリドマイド、チロシンキナーゼ阻害剤、mTOR阻害剤） - 移植片対宿主病治療の種類別販売量 - 移植片対宿主病治療の種類別売上 - 移植片対宿主病治療の種類別価格 ・用途別市場規模（急性GVHD、慢性GVHD、予防GVHD） - 移植片対宿主病治療の用途別販売量 - 移植片対宿主病治療の用途別売上 - 移植片対宿主病治療の用途別価格 ・北米市場 - 北米の移植片対宿主病治療市場規模（種類別、用途別） - 主要国別の移植片対宿主病治療市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの移植片対宿主病治療市場規模（種類別、用途別） - 主要国別の移植片対宿主病治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の移植片対宿主病治療市場規模（種類別、用途別） - 主要国別の移植片対宿主病治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の移植片対宿主病治療市場規模（種類別、用途別） - 主要国別の移植片対宿主病治療市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの移植片対宿主病治療市場規模（種類別、用途別） - 主要国別の移植片対宿主病治療市場規模（トルコ、サウジアラビア） ・企業情報 AbbVie Inc.、Acrofan、Astellas Pharma Inc.、Bristol-Myers Squibb Company、ElsaLys Biotech SA、F. Hoffmann-La Roche AG、Johnson & Johnson、Mallinckrodft PLC、Merck & Co., Inc.、Mesoblast Limited、Neovii Biotech GmbH、Novartis AG、Ocugen, Inc.、Pfizer Inc、Pluristem Therapeutics Inc.、Samedan Ltd、Sanofi SA、Soligenix, Inc. ・産業チェーン及び販売チャネル分析 - 移植片対宿主病治療の産業チェーン分析 - 移植片対宿主病治療の原材料 - 移植片対宿主病治療の生産プロセス - 移植片対宿主病治療の販売及びマーケティング - 移植片対宿主病治療の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 移植片対宿主病治療の産業動向 - 移植片対宿主病治療のマーケットドライバー - 移植片対宿主病治療の課題 - 移植片対宿主病治療の阻害要因 ・主な調査結果 |
Market Analysis and Insights: Global Graft Versus Host Disease Treatment Market
The global Graft Versus Host Disease Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Etanercept accounting for % of the Graft Versus Host Disease Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Acute GVHD segment is altered to an % CAGR throughout this forecast period.
China Graft Versus Host Disease Treatment market size is valued at US$ million in 2021, while the North America and Europe Graft Versus Host Disease Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Graft Versus Host Disease Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Graft Versus Host Disease Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Graft Versus Host Disease Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Graft Versus Host Disease Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Graft Versus Host Disease Treatment market.
Global Graft Versus Host Disease Treatment Scope and Market Size
Graft Versus Host Disease Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Graft Versus Host Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Etanercept
Monoclonal Antibodies
Thalidomide
Tyrosine Kinase Inhibitors
mTOR Inhibitors
Segment by Application
Acute GVHD
Chronic GVHD
Prophylaxis GVHD
By Company
AbbVie Inc.
Acrofan
Astellas Pharma Inc.
Bristol-Myers Squibb Company
ElsaLys Biotech SA
F. Hoffmann-La Roche AG
Johnson & Johnson
Mallinckrodft PLC
Merck & Co., Inc.
Mesoblast Limited
Neovii Biotech GmbH
Novartis AG
Ocugen, Inc.
Pfizer Inc
Pluristem Therapeutics Inc.
Samedan Ltd
Sanofi SA
Soligenix, Inc.
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Graft Versus Host Disease Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Etanercept
1.2.3 Monoclonal Antibodies
1.2.4 Thalidomide
1.2.5 Tyrosine Kinase Inhibitors
1.2.6 mTOR Inhibitors
1.3 Market by Application
1.3.1 Global Graft Versus Host Disease Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Acute GVHD
1.3.3 Chronic GVHD
1.3.4 Prophylaxis GVHD
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Graft Versus Host Disease Treatment Market Perspective (2017-2028)
2.2 Graft Versus Host Disease Treatment Growth Trends by Region
2.2.1 Graft Versus Host Disease Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Graft Versus Host Disease Treatment Historic Market Size by Region (2017-2022)
2.2.3 Graft Versus Host Disease Treatment Forecasted Market Size by Region (2023-2028)
2.3 Graft Versus Host Disease Treatment Market Dynamics
2.3.1 Graft Versus Host Disease Treatment Industry Trends
2.3.2 Graft Versus Host Disease Treatment Market Drivers
2.3.3 Graft Versus Host Disease Treatment Market Challenges
2.3.4 Graft Versus Host Disease Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Graft Versus Host Disease Treatment Players by Revenue
3.1.1 Global Top Graft Versus Host Disease Treatment Players by Revenue (2017-2022)
3.1.2 Global Graft Versus Host Disease Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Graft Versus Host Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Graft Versus Host Disease Treatment Revenue
3.4 Global Graft Versus Host Disease Treatment Market Concentration Ratio
3.4.1 Global Graft Versus Host Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Graft Versus Host Disease Treatment Revenue in 2021
3.5 Graft Versus Host Disease Treatment Key Players Head office and Area Served
3.6 Key Players Graft Versus Host Disease Treatment Product Solution and Service
3.7 Date of Enter into Graft Versus Host Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Graft Versus Host Disease Treatment Breakdown Data by Type
4.1 Global Graft Versus Host Disease Treatment Historic Market Size by Type (2017-2022)
4.2 Global Graft Versus Host Disease Treatment Forecasted Market Size by Type (2023-2028)
5 Graft Versus Host Disease Treatment Breakdown Data by Application
5.1 Global Graft Versus Host Disease Treatment Historic Market Size by Application (2017-2022)
5.2 Global Graft Versus Host Disease Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Graft Versus Host Disease Treatment Market Size (2017-2028)
6.2 North America Graft Versus Host Disease Treatment Market Size by Type
6.2.1 North America Graft Versus Host Disease Treatment Market Size by Type (2017-2022)
6.2.2 North America Graft Versus Host Disease Treatment Market Size by Type (2023-2028)
6.2.3 North America Graft Versus Host Disease Treatment Market Share by Type (2017-2028)
6.3 North America Graft Versus Host Disease Treatment Market Size by Application
6.3.1 North America Graft Versus Host Disease Treatment Market Size by Application (2017-2022)
6.3.2 North America Graft Versus Host Disease Treatment Market Size by Application (2023-2028)
6.3.3 North America Graft Versus Host Disease Treatment Market Share by Application (2017-2028)
6.4 North America Graft Versus Host Disease Treatment Market Size by Country
6.4.1 North America Graft Versus Host Disease Treatment Market Size by Country (2017-2022)
6.4.2 North America Graft Versus Host Disease Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Graft Versus Host Disease Treatment Market Size (2017-2028)
7.2 Europe Graft Versus Host Disease Treatment Market Size by Type
7.2.1 Europe Graft Versus Host Disease Treatment Market Size by Type (2017-2022)
7.2.2 Europe Graft Versus Host Disease Treatment Market Size by Type (2023-2028)
7.2.3 Europe Graft Versus Host Disease Treatment Market Share by Type (2017-2028)
7.3 Europe Graft Versus Host Disease Treatment Market Size by Application
7.3.1 Europe Graft Versus Host Disease Treatment Market Size by Application (2017-2022)
7.3.2 Europe Graft Versus Host Disease Treatment Market Size by Application (2023-2028)
7.3.3 Europe Graft Versus Host Disease Treatment Market Share by Application (2017-2028)
7.4 Europe Graft Versus Host Disease Treatment Market Size by Country
7.4.1 Europe Graft Versus Host Disease Treatment Market Size by Country (2017-2022)
7.4.2 Europe Graft Versus Host Disease Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Graft Versus Host Disease Treatment Market Size (2017-2028)
8.2 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Type
8.2.1 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Graft Versus Host Disease Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Application
8.3.1 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Graft Versus Host Disease Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Region
8.4.1 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Graft Versus Host Disease Treatment Market Size (2017-2028)
9.2 Latin America Graft Versus Host Disease Treatment Market Size by Type
9.2.1 Latin America Graft Versus Host Disease Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Graft Versus Host Disease Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Graft Versus Host Disease Treatment Market Share by Type (2017-2028)
9.3 Latin America Graft Versus Host Disease Treatment Market Size by Application
9.3.1 Latin America Graft Versus Host Disease Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Graft Versus Host Disease Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Graft Versus Host Disease Treatment Market Share by Application (2017-2028)
9.4 Latin America Graft Versus Host Disease Treatment Market Size by Country
9.4.1 Latin America Graft Versus Host Disease Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Graft Versus Host Disease Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Graft Versus Host Disease Treatment Market Size (2017-2028)
10.2 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Type
10.2.1 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Graft Versus Host Disease Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Application
10.3.1 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Graft Versus Host Disease Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country
10.4.1 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Graft Versus Host Disease Treatment Introduction
11.1.4 AbbVie Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.1.5 AbbVie Inc. Recent Developments
11.2 Acrofan
11.2.1 Acrofan Company Details
11.2.2 Acrofan Business Overview
11.2.3 Acrofan Graft Versus Host Disease Treatment Introduction
11.2.4 Acrofan Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.2.5 Acrofan Recent Developments
11.3 Astellas Pharma Inc.
11.3.1 Astellas Pharma Inc. Company Details
11.3.2 Astellas Pharma Inc. Business Overview
11.3.3 Astellas Pharma Inc. Graft Versus Host Disease Treatment Introduction
11.3.4 Astellas Pharma Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.3.5 Astellas Pharma Inc. Recent Developments
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Details
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.4.5 Bristol-Myers Squibb Company Recent Developments
11.5 ElsaLys Biotech SA
11.5.1 ElsaLys Biotech SA Company Details
11.5.2 ElsaLys Biotech SA Business Overview
11.5.3 ElsaLys Biotech SA Graft Versus Host Disease Treatment Introduction
11.5.4 ElsaLys Biotech SA Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.5.5 ElsaLys Biotech SA Recent Developments
11.6 F. Hoffmann-La Roche AG
11.6.1 F. Hoffmann-La Roche AG Company Details
11.6.2 F. Hoffmann-La Roche AG Business Overview
11.6.3 F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Introduction
11.6.4 F. Hoffmann-La Roche AG Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.6.5 F. Hoffmann-La Roche AG Recent Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Details
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Graft Versus Host Disease Treatment Introduction
11.7.4 Johnson & Johnson Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.7.5 Johnson & Johnson Recent Developments
11.8 Mallinckrodft PLC
11.8.1 Mallinckrodft PLC Company Details
11.8.2 Mallinckrodft PLC Business Overview
11.8.3 Mallinckrodft PLC Graft Versus Host Disease Treatment Introduction
11.8.4 Mallinckrodft PLC Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.8.5 Mallinckrodft PLC Recent Developments
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Company Details
11.9.2 Merck & Co., Inc. Business Overview
11.9.3 Merck & Co., Inc. Graft Versus Host Disease Treatment Introduction
11.9.4 Merck & Co., Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.9.5 Merck & Co., Inc. Recent Developments
11.10 Mesoblast Limited
11.10.1 Mesoblast Limited Company Details
11.10.2 Mesoblast Limited Business Overview
11.10.3 Mesoblast Limited Graft Versus Host Disease Treatment Introduction
11.10.4 Mesoblast Limited Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.10.5 Mesoblast Limited Recent Developments
11.11 Neovii Biotech GmbH
11.11.1 Neovii Biotech GmbH Company Details
11.11.2 Neovii Biotech GmbH Business Overview
11.11.3 Neovii Biotech GmbH Graft Versus Host Disease Treatment Introduction
11.11.4 Neovii Biotech GmbH Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.11.5 Neovii Biotech GmbH Recent Developments
11.12 Novartis AG
11.12.1 Novartis AG Company Details
11.12.2 Novartis AG Business Overview
11.12.3 Novartis AG Graft Versus Host Disease Treatment Introduction
11.12.4 Novartis AG Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.12.5 Novartis AG Recent Developments
11.13 Ocugen, Inc.
11.13.1 Ocugen, Inc. Company Details
11.13.2 Ocugen, Inc. Business Overview
11.13.3 Ocugen, Inc. Graft Versus Host Disease Treatment Introduction
11.13.4 Ocugen, Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.13.5 Ocugen, Inc. Recent Developments
11.14 Pfizer Inc
11.14.1 Pfizer Inc Company Details
11.14.2 Pfizer Inc Business Overview
11.14.3 Pfizer Inc Graft Versus Host Disease Treatment Introduction
11.14.4 Pfizer Inc Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.14.5 Pfizer Inc Recent Developments
11.15 Pluristem Therapeutics Inc.
11.15.1 Pluristem Therapeutics Inc. Company Details
11.15.2 Pluristem Therapeutics Inc. Business Overview
11.15.3 Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Introduction
11.15.4 Pluristem Therapeutics Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.15.5 Pluristem Therapeutics Inc. Recent Developments
11.16 Samedan Ltd
11.16.1 Samedan Ltd Company Details
11.16.2 Samedan Ltd Business Overview
11.16.3 Samedan Ltd Graft Versus Host Disease Treatment Introduction
11.16.4 Samedan Ltd Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.16.5 Samedan Ltd Recent Developments
11.17 Sanofi SA
11.17.1 Sanofi SA Company Details
11.17.2 Sanofi SA Business Overview
11.17.3 Sanofi SA Graft Versus Host Disease Treatment Introduction
11.17.4 Sanofi SA Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.17.5 Sanofi SA Recent Developments
11.18 Soligenix, Inc.
11.18.1 Soligenix, Inc. Company Details
11.18.2 Soligenix, Inc. Business Overview
11.18.3 Soligenix, Inc. Graft Versus Host Disease Treatment Introduction
11.18.4 Soligenix, Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.18.5 Soligenix, Inc. Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer